CompletedPhase 2NCT00448201
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Principal Investigator
- Thomas C. Shea, MDUNC Lineberger Comprehensive Cancer Center
- Intervention
- anti-thymocyte globulin(biological)
- Enrollment
- 71 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2011 – 2012
Study locations (1)
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00448201 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.